AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35320964 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl at 1μg.kg(‐1).h(‐1) and laparoscopic port site infiltration with 0.5% bupivacaine
Number of subjects: 100
Study 35026053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Music Therapy (GMT)
Number of subjects: 24
Study 35026053 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Choir Singing (RCS)
Number of subjects: 24
Study 35026053 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic music interventions
Number of subjects: 24
Study 35422056 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling practice of calligraphy (2 hours per week)
Number of subjects: 112
Study 35422056 — intervention group
Group type: COMPARATOR
Intervention: Usual practice of calligraphy (1 hour per week)
Number of subjects: 112
Study 33564230 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium fructoborate
Number of subjects: 0
Study 33564230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35929466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine intervention
Number of subjects: 1280
Study 35929466 — intervention group
Group type: COMPARATOR
Intervention: No fluoxetine intervention (Control)
Number of subjects: 1280
Study 32702298 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Number of subjects: 1077
Study 32702298 — intervention group
Group type: COMPARATOR
Intervention: MenACWY
Number of subjects: 1077
Study 32465125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 81
Study 32465125 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 81
Study 36380693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (10 mg/bid for 2 weeks)
Number of subjects: 116
Study 36380693 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 116
Study 34470599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 400 IU/day
Number of subjects: 87
Study 34470599 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D supplementation (control)
Number of subjects: 87
Study 32485656 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg MAS-ER
Number of subjects: 76
Study 32485656 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg MAS-ER
Number of subjects: 76
Study 32485656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 35331698 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 intervention
Number of subjects: 0
Study 35331698 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat effects
Number of subjects: 0
Study 35331698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold effects
Number of subjects: 0
Study 32330749 — intervention group
Group type: COMPARATOR
Intervention: Fast Food (FF) diet
Number of subjects: 10
Study 32330749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean (Med) diet
Number of subjects: 10
Study 34966061 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based meditative practices
Number of subjects: 0
Study 34966061 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 0
Study 34966061 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted training protocol for recruiters and interveners
Number of subjects: 0
Study 32147329 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 brackets with black tea
Number of subjects: 40
Study 32147329 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 brackets with Cola
Number of subjects: 40
Study 32147329 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 brackets with black tea
Number of subjects: 40
Study 32147329 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 brackets with Cola
Number of subjects: 40
Study 34299807 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting/monitoring screen time (ST)
Number of subjects: 252
Study 34299807 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to TV
Number of subjects: 252
Study 34299807 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent use of ST as a reward
Number of subjects: 252
Study 34299807 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting/monitoring ST
Number of subjects: 252
Study 36242996 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto2.0 program
Number of subjects: 5208
Study 36242996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5208
Study 36242996 — intervention group
Group type: EXPERIMENTAL
Intervention: Users group
Number of subjects: 5208
Study 32580919 — intervention group
Group type: EXPERIMENTAL
Intervention: ccIIV4 (Flucelvax®)
Number of subjects: 144
Study 32580919 — intervention group
Group type: COMPARATOR
Intervention: IIV4 (Fluzone ®)
Number of subjects: 144
Study 34463759 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) at four specific AA points (knee joint, shenmen, subcortex, and sympathesis)
Number of subjects: 62
Study 34463759 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupressure (non-acupuncture points on the auricular helix)
Number of subjects: 62
Study 33498445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish fed with fish oil diet (conventional fish, CF)
Number of subjects: 38
Study 33498445 — intervention group
Group type: COMPARATOR
Intervention: Fish fed with olive pomace-enriched diet (enriched fish, EF)
Number of subjects: 38
Study 32208351 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (3 cycles of epirubicin, cisplatin or oxaliplatin and capecitabine) followed by surgery and either postoperative chemotherapy or chemoradiotherapy (45Gy + cisplatin + capecitabine)
Number of subjects: 788
Study 32208351 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 788
Study 32208351 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy
Number of subjects: 788
Study 34480630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol 600 mg
Number of subjects: 52
Study 34480630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 34256130 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation with maximum airway pressure
Number of subjects: 9
Study 34256130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal recumbency
Number of subjects: 9
Study 34256130 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum airway pressure
Number of subjects: 9
Study 34256130 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scanning at a range of end‐inspiratory pressures
Number of subjects: 9
Study 34256130 — intervention group
Group type: EXPERIMENTAL
Intervention: Static compliance of the lungs
Number of subjects: 9
Study 34256130 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation at 10 cmH2O at 4 breaths min−1
Number of subjects: 9
Study 34818074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise for 25-40 min on 3-4 days per week for 14 ± 1 wk
Number of subjects: 0
Study 34818074 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 34818074 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (sit-to-stand maneuver)
Number of subjects: 0
Study 34818074 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise (exercise training)
Number of subjects: 0
Study 32986652 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stabilization technique (NST), performed for an average of 30 min per session, three times a week for six months
Number of subjects: 20
Study 32986652 — intervention group
Group type: COMPARATOR
Intervention: Control group received education for a home exercise program
Number of subjects: 20
Study 32666638 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 0
Study 32666638 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (Control)
Number of subjects: 0
Study 34902752 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-TLIF
Number of subjects: 102
Study 34902752 — intervention group
Group type: COMPARATOR
Intervention: MIS-TLIF
Number of subjects: 102
Study 33664007 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg per day)
Number of subjects: 50
Study 33664007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32785587 — intervention group
Group type: EXPERIMENTAL
Intervention: Total consumption questions
Number of subjects: 274
Study 32785587 — intervention group
Group type: EXPERIMENTAL
Intervention: Location-specific peak consumption questions (LSPC)
Number of subjects: 274
Study 32785587 — intervention group
Group type: EXPERIMENTAL
Intervention: Location-specific peak consumption questions (LSPC) first for heavy drinkers in the highest tercile
Number of subjects: 274
Study 35905339 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized phase estimation algorithm
Number of subjects: 0
Study 35905339 — intervention group
Group type: COMPARATOR
Intervention: Previous L‐independent approaches (e.g., qDRIFT)
Number of subjects: 0
Study 32666349 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic gel and lozenges (n=20)
Number of subjects: 40
Study 32666349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 36191882 — intervention group
Group type: EXPERIMENTAL
Intervention: Adebrelimab (20 mg/kg on day 1), nab-paclitaxel (100 mg/m2 on days 1, 8, and 15), and carboplatin (AUC 5 mg/mL per min on day 1) as neoadjuvant treatment followed by 16 cycles of adebrelimab (20 mg/kg on day 1 every 3 weeks) as adjuvant treatment.
Number of subjects: 37
Study 33951024 — intervention group
Group type: COMPARATOR
Intervention: Indwelling analgesic catheter (IC)
Number of subjects: 34
Study 33951024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose liposomal bupivacaine (LB)
Number of subjects: 34
Study 32648394 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-separated moxibustion applied at hypogastrium and lumbosacral area for 30 min, once a week for 3 months.
Number of subjects: 54
Study 32648394 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (no intervention except ibuprofen when necessary).
Number of subjects: 54
Study 35552166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring+Fitbit
Number of subjects: 243
Study 35552166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailoring only
Number of subjects: 243
Study 35552166 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 243
Study 35552166 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 243
Study 34098037 — intervention group
Group type: EXPERIMENTAL
Intervention: The Illicit Project program (a three-lesson, web-based program delivered fortnightly over 6 weeks)
Number of subjects: 8
Study 34098037 — intervention group
Group type: COMPARATOR
Intervention: Health education as usual (control group)
Number of subjects: 8
Study 34098037 — intervention group
Group type: EXPERIMENTAL
Intervention: The Illicit Project program
Number of subjects: 8
Study 32251303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement during the 4-day interval before PCI
Number of subjects: 108
Study 32251303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction (DR) - formula diet containing 60% of daily energy requirement
Number of subjects: 108
Study 34511586 — intervention group
Group type: EXPERIMENTAL
Intervention: IV OPC‐61815 16 mg
Number of subjects: 60
Study 34511586 — intervention group
Group type: COMPARATOR
Intervention: Oral tolvaptan 15 mg
Number of subjects: 60
Study 32001003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75
Study 32001003 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Psychodynamic Psychotherapy
Number of subjects: 75
Study 32001003 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic controls (treatment as usual)
Number of subjects: 75
Study 36309660 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 35
Study 36309660 — intervention group
Group type: COMPARATOR
Intervention: Venturi Mask (VM)
Number of subjects: 35
Study 34085505 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIOS group (digital impressions using Trios Pod Scanner)
Number of subjects: 24
Study 34085505 — intervention group
Group type: EXPERIMENTAL
Intervention: CEREC group (digital impressions using Cerec AC Omnicam)
Number of subjects: 24
Study 34085505 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional impressions using polyvinyl siloxane silicone material)
Number of subjects: 24
Study 34085505 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (comparison of continuous margin evaluations)
Number of subjects: 24
Study 33449534 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulfate (400 mg/day intravenously for 4 days, followed by oral administration at 400 mg/day for 6 days)
Number of subjects: 95
Study 33449534 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy according to the order of the Ministry of Health of the Russian Federation No. 928n
Number of subjects: 95
Study 33449534 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulfate
Number of subjects: 95
Study 35715574 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal TDCS (2 mA, 20 min) on intact SMG
Number of subjects: 44
Study 35715574 — intervention group
Group type: COMPARATOR
Intervention: Sham TDCS (30 s, 5 sessions)
Number of subjects: 44
Study 34967830 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 0
Study 34967830 — intervention group
Group type: COMPARATOR
Intervention: Sham control (riboflavin ophthalmic solution)
Number of subjects: 0
Study 32369007 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised speech and language therapy
Number of subjects: 240
Study 32369007 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 32369007 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 240
Study 35870491 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 50
Study 35870491 — intervention group
Group type: EXPERIMENTAL
Intervention: UT‐DSAEK
Number of subjects: 50
Study 34179925 — intervention group
Group type: COMPARATOR
Intervention: Exercise group (E)
Number of subjects: 69
Study 34179925 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus high-protein group (EP)
Number of subjects: 69
Study 33128502 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg group (1 egg per day for 6 months)
Number of subjects: 660
Study 33128502 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study 34399136 — intervention group
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (DOT) using a HIPAA-compliant smartphone application
Number of subjects: 78
Study 34399136 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 78
Study 35427407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant members (D)
Number of subjects: 23
Study 35427407 — intervention group
Group type: COMPARATOR
Intervention: Adductors
Number of subjects: 23
Study 33528004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program, performed before treatment, with 12 to 18 sessions of tailored, high‐intensity exercise and post‐exercise recovery strategies.
Number of subjects: 120
Study 33528004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Therapeutic Exercise and Recovery Strategies (ATOPE) program
Number of subjects: 120
Study 32861537 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 375
Study 32861537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 35422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM)
Number of subjects: 30
Study 35422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided design NAM (CAD/NAM)
Number of subjects: 30
Study 33612068 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-test; if PSA ≥ 3 ng/mL, then MRI and systematic biopsy, plus targeted biopsy to suspicious lesions as per PI-RADSv2 3–5
Number of subjects: 38770
Study 33612068 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-test; if PSA ≥ 3 ng/mL, then MRI, and targeted biopsy only if PI-RADSv2 3–5
Number of subjects: 38770
Study 33612068 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical to Arm 2, except lower PSA-cut-off ≥1.8 ng/mL
Number of subjects: 38770
Study 33612068 — intervention group
Group type: COMPARATOR
Intervention: PSA-screening and systematic biopsy
Number of subjects: 38770
Study 32307933 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPUS therapy combined with Twin-Block appliance
Number of subjects: 45
Study 32307933 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-Block appliance only
Number of subjects: 45
Study 32307933 — intervention group
Group type: COMPARATOR
Intervention: Control group (observational, no treatment)
Number of subjects: 45
Study 35155721 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 50
Study 35155721 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 50
Study 32366163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1803
Study 32366163 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO quartile 4
Number of subjects: 1803
Study 32366163 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO quartile 4 after adjustment for clinical factors
Number of subjects: 1803
Study 32366163 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO quartile 4 after adjustment for cardiovascular biomarkers
Number of subjects: 1803
Study 35862001 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric multifactorial diet rich in MUFA, polyunsaturated fatty acids, fiber, polyphenols, and vitamins (n = 18)
Number of subjects: 39
Study 35862001 — intervention group
Group type: COMPARATOR
Intervention: MUFA-rich diet (n = 21)
Number of subjects: 39
Study 35862001 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric multifactorial diet
Number of subjects: 39
Study 35862001 — intervention group
Group type: COMPARATOR
Intervention: MUFA-rich diet
Number of subjects: 39
Study 34028967 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily plus 177Lu-PSMA-617 7.5 GBq on Days 15 and 57 (up to four doses total)
Number of subjects: 160
Study 34028967 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide 160 mg daily alone
Number of subjects: 160
Study 32618249 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) malaria interventions
Number of subjects: 0
Study 32618249 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC plus focal mass drug administration (fMDA)
Number of subjects: 0
Study 32618249 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC plus mass drug administration (MDA)
Number of subjects: 0
Study 35545875 — intervention group
Group type: COMPARATOR
Intervention: Topical product (Group C) - cream formulation containing hydroxypinacolone/retinyl palmitate, Iris Florentina root extract, and a complex of three oligopeptides applied twice a day.
Number of subjects: 184
Study 35545875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Group C + O) - topical product plus prebiotic food supplement (FOS&GOS, zinc, lactoferrin, niacinamide).
Number of subjects: 184
Study 34692934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy group (HT) with innovative aquatic proprioceptive training plus conventional rehabilitation for 6 weeks
Number of subjects: 38
Study 34692934 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group (CT) with conventional rehabilitation for 6 weeks
Number of subjects: 38
Study 35178237 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MA) with CT monitoring
Number of subjects: 96
Study 35178237 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MA) with MRI monitoring
Number of subjects: 96
Study 35178237 — intervention group
Group type: COMPARATOR
Intervention: Comparison of inactivation rates between CT and MRI groups
Number of subjects: 96
Study 33677771 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) alone
Number of subjects: 218
Study 33677771 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon alpha2a (Peg‐IFN‐α‐2a) add‐on
Number of subjects: 218
Study 32122311 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME intervention (patient-centered discharge planning led by an occupational therapist)
Number of subjects: 400
Study 32122311 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME intervention
Number of subjects: 400
Study 32122311 — intervention group
Group type: COMPARATOR
Intervention: Structured in-hospital consultation (Control)
Number of subjects: 400
Study 34749418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 38
Study 34749418 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 38
Study 34749418 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38
Study 32972478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PBCT within SVC
Number of subjects: 95
Study 32972478 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice (SVC)
Number of subjects: 95
Study 33919721 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of tribal identity
Number of subjects: 579
Study 33919721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribal language proficiency
Number of subjects: 579
Study 34955484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated BRP dentifrice
Number of subjects: 42
Study 34955484 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated common dentifrice
Number of subjects: 42
Study 32087745 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred approach in the trial
Number of subjects: 64
Study 32087745 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred processes including home visits and assistance with questionnaires
Number of subjects: 64